Acer Therapeutics Overview
- Status
-
Acquired/Merged
- Employees
-
39
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$73M
Acer Therapeutics General Information
Description
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Contact Information
Website
www.acertx.comCorporate Office
- One Gateway Center, 300 Washington Street
- Suite 356
- Newton, MA 02458
- United States
Corporate Office
- One Gateway Center, 300 Washington Street
- Suite 356
- Newton, MA 02458
- United States
Acer Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 17-Nov-2023 | $73M | Completed | Generating Revenue | ||
| 11. PIPE | 24-Mar-2023 | Completed | Generating Revenue | |||
| 10. 2PO | 24-Mar-2023 | Completed | Generating Revenue | |||
| 9. PIPE | 02-Dec-2022 | Completed | Generating Revenue | |||
| 8. Debt - General | 07-Mar-2022 | Completed | Generating Revenue | |||
| 7. PIPE | 01-Dec-2021 | Completed | Generating Revenue | |||
| 6. PIPE | 24-Jul-2020 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 4. Reverse Merger | 19-Sep-2017 | $26M | Completed | Generating Revenue | ||
| 3. Later Stage VC | 01-Jan-2017 | $15.7M | $26M | Completed | Clinical Trials - General |
Acer Therapeutics Comparisons
Industry
Financing
Details
Acer Therapeutics Competitors (84)
One of Acer Therapeutics’s 84 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Protalix Biotherapeutics | Formerly VC-backed | Karmiel, Israel | ||||
| Astellas Pharma | Corporation | Tokyo, Japan |
Acer Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Acer Therapeutics Patents
Acer Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024206981-A2 | Methods of treating liver and kidney conditions with phenylbutyrate | Inactive | 31-Mar-2023 | ||
| WO-2024206981-A3 | Methods of treating liver and kidney conditions with phenylbutyrate | Inactive | 31-Mar-2023 | ||
| WO-2023147134-A2 | Methods for treating patients having low estrogen with nk3 antagonists | Inactive | 31-Jan-2022 | ||
| WO-2023147135-A1 | Nk receptor antagonists for treatment of prostate cancer | Inactive | 31-Jan-2022 | ||
| WO-2023147134-A3 | Nk3 antagonists for treating patients having low estrogen | Inactive | 31-Jan-2022 | A61K31/4545 |
Acer Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Acer Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bukwang Pharmaceutical | Corporation | Minority | ||
| Opexa Therapeutics | Corporation | Minority | ||
| TVM Capital Life Science | Venture Capital | Minority |
Acer Therapeutics Investments & Acquisitions (3)
Acer Therapeutics’s most recent deal was a Corporate Asset Purchase with Sanofi (Osanetant). The deal was made on 02-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sanofi (Osanetant) | 02-Jan-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Opexa Therapeutics | 19-Sep-2017 | Merger/Acquisition | Biotechnology | ||
| Anchor Therapeutics | 20-Mar-2015 | Merger/Acquisition | Drug Discovery |
Acer Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Acer Therapeutics FAQs
-
Where is Acer Therapeutics headquartered?
Acer Therapeutics is headquartered in Newton, MA.
-
What is the size of Acer Therapeutics?
Acer Therapeutics has 39 total employees.
-
What industry is Acer Therapeutics in?
Acer Therapeutics’s primary industry is Drug Discovery.
-
Is Acer Therapeutics a private or public company?
Acer Therapeutics is a Private company.
-
What is the current valuation of Acer Therapeutics?
The current valuation of Acer Therapeutics is .
-
What is Acer Therapeutics’s current revenue?
The current revenue for Acer Therapeutics is .
-
How much funding has Acer Therapeutics raised over time?
Acer Therapeutics has raised $83M.
-
Who are Acer Therapeutics’s investors?
Bukwang Pharmaceutical, Opexa Therapeutics, and TVM Capital Life Science have invested in Acer Therapeutics.
-
Who are Acer Therapeutics’s competitors?
BioMarin Pharmaceutical, Dicerna Pharmaceuticals, Renova Therapeutics, Protalix Biotherapeutics, and Astellas Pharma are some of the 84 competitors of Acer Therapeutics.
-
When was Acer Therapeutics acquired?
Acer Therapeutics was acquired on 17-Nov-2023.
-
Who acquired Acer Therapeutics?
Acer Therapeutics was acquired by Zevra Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
